FDA Drug Recalls

Recalls / Class II

Class IID-0205-2024

Product

Sertraline Tablets, USP 100 mg, 30 tablets per bottle, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, Packaged by: Legacy Pharmaceutical Packaging LLC., Earth City, MO 63045, NDC# 68645-523-54

Brand name
Sertraline Hydrochloride
Generic name
Sertraline Hydrochloride
Active ingredient
Sertraline Hydrochloride
Route
Oral
NDCs
68645-521, 68645-522, 68645-523
FDA application
ANDA077397
Affected lot / code info
Lot #: 222033, exp. date 08/31/2024

Why it was recalled

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Recalling firm

Firm
Legacy Pharmaceutical Packaging LLC
Manufacturer
Legacy Pharmaceutical Packaging, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
13333 Lakefront Dr, Earth City, Missouri 63045-1514

Distribution

Quantity
161,664 bottles
Distribution pattern
CA and AR

Timeline

Recall initiated
2023-12-11
FDA classified
2023-12-26
Posted by FDA
2024-01-03
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0205-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.